1. Home
  2. NXL vs LSTA Comparison

NXL vs LSTA Comparison

Compare NXL & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXL
  • LSTA
  • Stock Information
  • Founded
  • NXL 2010
  • LSTA 1980
  • Country
  • NXL United States
  • LSTA United States
  • Employees
  • NXL N/A
  • LSTA N/A
  • Industry
  • NXL Medical Specialities
  • LSTA Misc Health and Biotechnology Services
  • Sector
  • NXL Health Care
  • LSTA Health Care
  • Exchange
  • NXL Nasdaq
  • LSTA Nasdaq
  • Market Cap
  • NXL 17.8M
  • LSTA 20.9M
  • IPO Year
  • NXL 2022
  • LSTA N/A
  • Fundamental
  • Price
  • NXL $1.52
  • LSTA $2.44
  • Analyst Decision
  • NXL Strong Buy
  • LSTA Strong Buy
  • Analyst Count
  • NXL 1
  • LSTA 2
  • Target Price
  • NXL $5.00
  • LSTA $23.50
  • AVG Volume (30 Days)
  • NXL 10.4M
  • LSTA 42.6K
  • Earning Date
  • NXL 11-07-2025
  • LSTA 11-11-2025
  • Dividend Yield
  • NXL N/A
  • LSTA N/A
  • EPS Growth
  • NXL N/A
  • LSTA N/A
  • EPS
  • NXL N/A
  • LSTA N/A
  • Revenue
  • NXL $174,813.00
  • LSTA $1,070,000.00
  • Revenue This Year
  • NXL $38.28
  • LSTA N/A
  • Revenue Next Year
  • NXL $185.71
  • LSTA N/A
  • P/E Ratio
  • NXL N/A
  • LSTA N/A
  • Revenue Growth
  • NXL 16.42
  • LSTA N/A
  • 52 Week Low
  • NXL $0.70
  • LSTA $1.87
  • 52 Week High
  • NXL $4.49
  • LSTA $4.20
  • Technical
  • Relative Strength Index (RSI)
  • NXL 61.70
  • LSTA 49.36
  • Support Level
  • NXL $1.20
  • LSTA $2.35
  • Resistance Level
  • NXL $1.46
  • LSTA $2.61
  • Average True Range (ATR)
  • NXL 0.17
  • LSTA 0.16
  • MACD
  • NXL 0.04
  • LSTA -0.00
  • Stochastic Oscillator
  • NXL 57.89
  • LSTA 35.71

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: